This study presents evidence of genetic NF1 loss in human second malignant neoplasms and in vivo experimental evidence showing that Nf1 heterozygosity confers broad susceptibility to genotoxininduced tumorigenesis. patients. Nf1 heterozygosity confers broad susceptibility to genotoxin-induced tumorigenesis and this paradigm serves as an experimental platform for future studies of SMNs.
Introduction
Secondary malignant neoplasms (SMNs) are late complications arising after exposure to genotoxins.
These cancers can arise from a variety of tissues within an irradiated anatomic compartment (1) (2) (3) , reflecting the wide range of cell types sharing susceptibility to mutagenesis. It is currently not possible to predict which patients will develop an SMN nor are there known shared mechanisms linking the pathogenesis of diverse SMN histologies. The incidence of SMNs is growing primarily because the number of pediatric and other at-risk cancer survivors has increased over the last few decades (4) (5) (6) .
The mechanisms underlying SMN development are very poorly understood, with radiation exposure and young age at the time of treatment being the strongest risk factors (2, 3, 7, 8) . Defining the mechanisms responsible for SMN pathogenesis is critical to developing strategies to accurately predict and mitigate this risk in current and future cancer survivors. Mechanistic analyses of both patient and treatment factors are difficult to perform through retrospective clinical analyses, and thus experimental models of SMNs are needed.
Genetic background contributes to tumor susceptibility in humans and mice, for example, the high frequency of SMNs arising in the setting of Li-Fraumeni syndrome and other genetic disorders of DNA repair (9, 10) . Furthermore, experimental models of radiation-induced tumorigenesis do not replicate radiotherapy delivery and often employ genetically unstable mouse strains. The resultant tumors do not reconstitute the full spectrum of histologies comprising SMNs, and the latency to tumor development is often extremely abbreviated (within a few months) in contrast to the latency of SMNs in humans, which is over several years and sometimes decades. The inability to broadly model SMN risk in relation to relevant radiotherapy variables of dose, fractionation and targeting has limited our understanding of how clinical treatment, patient variables and environmental exposures influence SMN risk. As a result, there are no validated approaches to predicting or preventing SMNs in at-risk individuals, such as survivors of childhood cancers.
Heterozygosity for the NF1 gene causes the Neurofibromatosis I Syndrome (NF1), and individuals with NF1 are at increased risk of developing SMNs after radiotherapy (11) . The NF1 gene, and its conserved murine homologue Nf1, encode the protein neurofibromin, which is ubiquitously expressed in mammalian cells and necessary for development (12) . Neurofibromin possesses a GTPase activating protein (GAP) domain, a region that negatively regulates Ras signaling (13) (14) (15) (16) .
We hypothesized that the clinical susceptibility of NF1 patients to SMN development could be modeled in Nf1 mutant mice to study SMN pathogenesis. In earlier work, we showed that focal, fractionated cranial irradiation of Nf1 +/-mice produced both hematologic and in-field solid malignancies (17) . To develop a more robust model that 1) tested whether focal fractionated irradiation potentiates tumorigenesis among diverse tissues and 2) efficiently generated large numbers of tumors in both genetically resistant and susceptible backgrounds for analysis we delivered abdominal irradiation to wildtype and Nf1 mutant mice. We replicated a clinical paradigm using customized techniques to deliver focal, fractionated radiation to the abdomen (AI) (0 Gy, 3 Gy, 15 Gy or 30 Gy) ( Figure 1 and Supplementary Figure 1 ). This procedure concentrates radiation exposure to the superficial tissues and generates a dose gradient to deeper internal organs, permitting the safe delivery of radiation doses that would be lethal as whole body exposures. This application of fractionation mimics clinical radiotherapy practice and was an approach we used in our cranial irradiation model (17) . with a common pathogenetic mechanism of Nf1-dependent tumorigenesis active in multiple cell types.
Interestingly, this signature loss was also present in a subset of radiation-induced tumors from wildtype mice, which lost either parental allele at similar frequencies. This suggests that Nf1 haploinsufficiency can drive radiation-induced tumor formation in the wildtype background as well, and may be a genetic mechanism promoting radiation-induced tumors in between different genetic backgrounds. We extended our genetic analysis to human radiation-induced breast cancers and identified loss of heterozygosity of NF1 in a subset of these SMNs from unrelated individuals without NF1. These findings suggest that Nf1 loss in our mouse model mirrors NF1 loss in human SMNs and suggest that targeting the biochemical consequences of NF1 loss may be a useful strategy against SMN development.
Materials and Methods

Mouse Strains, Breeding and Treatment
Nf1
+/-and wildtype mice were generated as previously described (18) . In brief, Nf1 +/-mice maintained in the 129/Sv background (19) were crossed with wild-type C57Bl/6 mice. Mice were placed in a cesium-137 source (J.L. Shepherd & Associates, San Fernando, CA) animal irradiator and shielded with an iron collimator that focused the beam width. Five to eight week old mice were given abdominal irradiation at a fractionation of either one fraction of 3 Gy, five fractions of 3 Gy or ten fractions of 3 Gy, delivered at a rate of five fractions per week, one fraction per day. The UCSF IACUC approved all animal procedures.
Pathologic Analysis
Animals were followed for a minimum of 18 months post-irradiation. Animals with signs of systemic illness were euthanized and visible masses/growths, peripheral blood, and bone marrow were collected immediately. The mice were then perfused with 4% paraformaldehyde and the following organs were collected: brain, skin in irradiated region, skin outside irradiated region, skull, heart, lungs, spleen, liver, reviewed by a pathologist (AH), who delineated tumor and normal areas for dissection. Tumor and normal tissues were then dissected off of unstained slides and genomic DNA was isolated and subjected to whole genome amplification according to manufacturers instructions using the REPLI-g FFPE kit (Qiagen). DNA was purified using sodium acetate, and quantified using Picogreen (Qiagen).
Mouse tumor Genotyping and Mutation Analysis
Taqman SNP Genotyping
Analysis of clinical samples was performed with approval from the UCSF Committee on Human All samples were run in replicates of 6. Allelic discrimination plots generated by SDS3.0, an Applied
Biosystems program used to make genotyping calls.
Trp53 sequencing
Whole exomic sequencing was performed to assess for the presence of mutations in the Trp53 gene.
Two kb fragments of the Trp53 gene spanning exons 2-4, 5-7, and 8-10 were PCR-amplified from all primary tumor and select matching tail DNA samples. Similarly, 1 kb fragments were PCR amplified from exons 1 and 11. PCR amplification was performed with Qiagen Taq DNA polymerase. PCR cleanup was done with ExoSAP-IT (Affymetrix). The PCR fragments were then sequenced (Quintara Biosciences) with sequencing primers (listed in Supplementary Sanger Institute, United Kingdom) was used to search for references to human tumors also possessing the identified mutations.
Statistical Analysis
Survival curves are calculated from Kaplan-Meier product limit estimators to determine the association of CI on mortality. Log-rank tests are used to test for differences in survival curves between groups. All analyses were performed using Prizm v.4 (GraphPad).
Results
High dose AI reduces survival in Nf1 mutant mice but not wildtype mice
In irradiated cancer survivors, the risk of SMNs is well recognized although the precise SMN histology can be difficult to predict. Furthermore, cancer survivors may develop multiple subsequent malignancies and diverse SMNs over time (1) . Multi-organ SMN development is therefore not well-modeled using tissue-restricted conditional mutations. To replicate whole organismal tumor susceptibility we sought to model the germline Nf1 loss responsible for the NF1 syndrome.
To establish a homogeneous genetic background, we intercrossed wildtype (WT) C57BL6 and 
AI drives multi-organ tumorigenesis in WT and Nf1 +/-mice
Necropsy revealed multi-organ abnormalities after irradiation. Hematologic malignancies such as myeloproliferative neoplasms and leukemias can arise as secondary malignancies after radiation exposure (20) . To screen for this we assessed spleen and liver weight and performed a complete blood count (CBC) at the time of euthanasia and found significantly increased mean terminal splenic weight in unirradiated Nf1 +/-mice as compared to WT mice (Supplementary Figure 2A) Kingdom) revealed that each of these mutations occur in diverse human cancers ( Figure 6A ).
In contrast to tumors arising in Nf1 mutant mice, most tumors from WT mice demonstrated intact heterozygosity at the tested markers ( Figure 5D ). However, surprisingly in five WT tumors we identified segmental loss of Nf1 and Trp53, similar to tumors arising in Nf1 +/-mice. This suggests that concurrent loss of these genes is also an important mechanism for radiation-induced tumorigenesis in a WT background. Among these WT tumors, segmental LOH involved either parental allele at similar frequency ( Figure 5D ), consistent with allelic loss that is unbiased by an inactivated allele on either parental strand. This pattern stands in contrast to segmental LOH in tumors derived from the Nf1 +/-mice, in which the mutant Nf1 allele is maintained on the Sv129-derived allele and preferential loss of the C57Bl/6-derived allele occurred. 
Somatic loss of NF1 occurs in human radiation-induced breast cancers
The genetic basis of human SMNs is poorly understood, most likely due to the scarcity of high quality SMN tissue samples. Our mouse model implicates Nf1 loss as an important driver of SMN development, but the incidence of and significance of NF1 loss in human SMNs are not known. We assessed NF1 status in human radiation-induced breast cancers, which are well recognized SMNs developing in women who receive chest irradiation as children (7, 26) . Radiation-induced breast cancers and matched normal tissue from patients (8 total patients, none known to have the NF1 syndrome) were analyzed using Taqman 
Discussion
The pathogenesis of SMNs is not well understood, but clinical analyses indicate that the process is influenced by both cancer therapies and features of cancer patients themselves. In addition to radiotherapy, chemotherapeutic agents such as alkylating agents and topoisomerase II inhibitors such as epipodophyllotoxin have been associated with SMN development (23, 27) . In particular, leukemias as therapy-induced malignancies have been associated with chemotherapies (28, 29) . Genetic tumor predisposition syndromes are associated with SMN risk (7), and individuals with strong family histories of cancer also have enhanced risk. SMNs are substantially more likely to arise in patients treated as young children (6) . Post-treatment endocrinopathies and obesity are common in survivors of pediatric cancers, and may also influence risk of SMNs known to be hormone-sensitive such as breast cancer (30) . Taken together, our data in wildtype and Nf1 +/-mice suggest that genomic injury after radiation exposure resulting in monoallelic somatic loss of NF1 and Trp53 is a common genetic mechanism that promotes radiation-induced tumors. Loss or inactivation of the remaining NF1 allele may be a critical secondary event that accelerates tumorigenesis in multiple tissue types, as evidenced by the marked susceptibility of Nf1 +/-mice, which already bear the first of presumably two required losses. However, since we detected LOH of NF1 in human samples another possibility is that the upregulation of Ras signaling apparent with monoalleleic NF1 loss is a primed signaling backdrop that increases the efficiency with which additional alterations, for example in growth-factor mediated signaling, promote cell proliferation and transformation. Genomic and proteomic analyses of these tumors may be particularly productive for identifying these cooperating pathways.
Genome-wide association studies (GWAS) have identified potential predictors of cancer susceptibility in cancer survivors (34, 35) . Experimental validation is needed to justify and optimize testing chemoprevention strategies for patients. As a result, our model fills a vital role in studies of SMN susceptibility and the pre-clinical validation of chemopreventive strategies against SMNs. , and metastases (C) are shown for each experimental group. Tumors were more common in Nf1 +/-mice than WT mice, and for Nf1 +/-mice tumor incidence increased with increasing radiation dose (p < 0.0001 by χ 2 analysis), while for WT mice, a relationship between tumor incidence and radiation dose failed to reach significance (p= 0.0511 by χ 2 analysis). Synchronous tumorigenesis occurred in both WT and Nf1 +/-mice, with synchronous malignancies in the Nf1 +/-background increasing with increasing radiation doses (p= 0.0264 by χ 2 analysis). Kaplan-Meier survival analysis of WT mice shows no significant dose response for death due to either solid tumor or hematologic disease (log rank test, p=0.13 for solid tumor free survival, p=0.68 for hematologic disease free survival).
In contrast, Nf1 mutant mice demonstrate a dose response for both solid tumor and hematologic disease-related death (log rank test, p<0.0001 for solid tumor free survival and p=0.0001 for hematologic disease free survival). 
